Marstacimab Dosage

Medically reviewed by Drugs.com. Last updated on Feb 4, 2025.

Applies to the following strengths: hncq 150 mg/mL

Usual Adult Dose for Bleeding

Loading dose: 300 mg subcutaneously (two 150 mg injections)
Maintenance dose: 150 mg subcutaneously every week

Comments:

The dose may be increased to 300 mg every week for patients weighing 50 kg or more if bleeding control is inadequate. Safety and efficacy at doses above 300 mg every week have not been established.

Use: To prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B without inhibitors

Usual Pediatric Dose for Bleeding

12 years or older:
Loading dose: 300 mg subcutaneously (two 150 mg injections)
Maintenance dose: 150 mg subcutaneously every week

Comments:

The dose may be increased to 300 mg every week for patients weighing 50 kg or more if bleeding control is inadequate. Safety and efficacy at doses above 300 mg every week have not been established.

Use: To prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B without inhibitors

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Before starting this drug, discontinue clotting factor concentrates (factor VIII or IX).
For subcutaneous use only.
Before subcutaneous administration, allow this drug to warm at room temperature in its carton for 15-30 minutes, avoiding direct sunlight, and use within 7 days or discard.
Visually inspect for particulate matter and discoloration before administration. Do not use if the solution is cloudy, dark yellow, or contains flakes or particles.
Administer maintenance dose one week after the loading dose.
Administer dose on the same day every week, at any time of the day, preferably in the abdomen or thigh.
Administration in the upper arm (prefilled syringe) or buttocks (prefilled pen) should be performed by a caregiver or healthcare professional.
If more than two injections are required to deliver a complete dose, administer each injection at a different injection site.
Do not inject into bony areas or areas with bruising, redness, tenderness, hardness, scars, or stretch marks, and it should not be injected into a vein. Rotate the injection site with each dose.
This drug is not for IV use.

Missed Dose:

If a 150 mg maintenance dose is missed, administer as soon as possible before the next scheduled dose. If more than 13 days have passed since the last dose, administer a 300 mg loading dose subcutaneously and continue with the same or new schedule based on the date of administration of missed dose thereafter.
If a 300 mg maintenance dose is missed, administer as soon as possible and continue with the same or new schedule based on the date of administration of missed dose thereafter.

Storage requirements:

Refrigerate at 36F to 46F (2C to 8C) in the original carton to protect from light.
This drug can be stored at room temperature up to 30C (86F) for up to 7 days in its original carton but must not be returned to the refrigerator and should be discarded after 7 days.
Do not freeze or shake.

General:

Factor VIII and IX products can be used to treat breakthrough bleeds in patients receiving this drug, but additional doses of this drug should not be used for this purpose.
This drug has not been evaluated in a setting of a major surgery. For major surgery, discontinue this drug and manage with clotting factor concentrate and measures to manage the risk of venous thrombosis.
Refer to clotting factor product information for dosage guidelines.
Resume this drug based on the patient's clinical status, including post-surgical thromboembolic risk factors and other treatments.
There is limited experience with this drug in patients with acute severe illness.
Treatment with this drug may be temporarily interrupted during serious conditions (e.g., serious infection, sepsis, trauma) due to increased coagulation risks. The illness should be managed according to local standards, and the continuation of treatment should be carefully evaluated for risks. Therapy can resume once the patient has recovered.

Patient advice:

Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
After proper training in subcutaneous injection technique, the patient or caregiver may administer the drug, if appropriate.
Seek immediate medical attention if any signs or symptoms of thromboembolism occur.
Seek immediate emergency treatment if a severe hypersensitivity reaction occurs.
Females of childbearing potential should use effective contraception during treatment with this drug and for 2 months after the last dose.
Advise patients to report known pregnancies.